This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
FLOW - El Resumen Visual
¡La Marea de Semaglutida llegó a la Enfermedad Renal Crónica!
Del monstruo de Gila al estudio FLOW.
Para ello, veamos el hermoso resumen visual realizado por la pasante de NephEdC, Anjana Gopal, traducido por Milagros Flores.
FLOW- the Visual Abstract
‘FLOW’ing with the Semaglu’TIDE’!
Check the beautiful visual abstract made by NephEdC intern Anjana Gopal, with an appearance of the Gila monster as well.
FLOWing with the SemagluTIDE
🤔 EMPA KIDNEY analysis by CKD diagnosis
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (The EMPA-KIDNEY Collaborative Group The Lancet 2023)
🤔 EMPA Kidney sub-group analysis by DM and ACR status
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (The EMPA-KIDNEY Collaborative Group 2023)
🤔 Albuminuria reduction drives Finerenone's kidney benefit
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes (Agarwal et al, Annals IM 2023)
Two’s Company but Three maybe the Winner? Aldosterone Synthase Inhibition added to RASi + Flozin
Zibotentan and Flozins: Climbing to the ZENITH of nephroprotection?
Closed Loop Sugar Control: The Visual Abstract
Brilliant VA by Sharanya Ramesh for this week’s NephJC on safety and efficacy of fully closed-loop insulin therapy in patients with type 2 diabetes requiring dialysis.
Visual abstract for FIDELIO
Beautiful visual abstract by Dhwanil Patel
